Inspire Medical Systems, Inc.

Inspire Medical Systems reported Q2 2026 revenue of $200.6 million, a decrease from $217.1 million in Q2 2025, but achieved net earnings of $0.3 million, a significant improvement from a net loss of $3.6 million in the prior year quarter. For the first six months of 2026, revenue was $405.2 million, down from $418.4 million, with a net loss of $11.0 million compared to a $0.6 million loss in the same period last year. The company generated $36.1 million in cash from operations for the six months ended June 30, 2026, a substantial increase from a cash outflow in the prior year. Additionally, a securities class action lawsuit was transferred to Minnesota and an amended complaint was filed.

Inspire Medical Systems reported Q2 2026 financial results, with revenue decreasing 7.6% to $200.6 million, primarily due to U.S. revenue decline. Diluted EPS was $0.01, and adjusted diluted EPS was $0.14. The company raised its full-year 2026 revenue outlook to $835 million to $875 million and expects adjusted diluted EPS of $1.05 to $1.45. Additionally, Inspire announced a strategic growth plan, Project Horizon, involving $20 million to $25 million in restructuring charges to unlock $30 million in annualized growth investment capacity.

Inspire Medical Systems reported Q2 2026 financial results, with revenue of $200.6 million and diluted EPS of $0.01, or $0.14 adjusted. The company also announced a strategic growth plan, 'Project Horizon,' designed to generate $30 million in annualized growth investment capacity for targeted initiatives. Despite a 7.6% decrease in Q2 revenue year-over-year, primarily due to U.S. reimbursement changes, gross margin improved to 85.5% and operating cash flow was $23.2 million. Inspire raised its full-year 2026 revenue outlook to $835 million-$875 million and adjusted operating margin to 4%-6%.

Inspire Medical Systems, Inc. announced the appointment of Michael H. Carrel to its Board of Directors, effective July 20, 2026. Mr. Carrel, age 55, brings extensive experience from the medical device and technology sectors, including his current role as President and CEO of AtriCure, Inc. He will serve as a Class III director and join the Organization and Compensation Committee and Quality, Product Supply and Technology Committee. His compensation includes annual cash retainers and equity awards totaling $500,000 initially.

Inspire Medical Systems announced that Casey Tansey, a member of its Board of Directors, will retire from the Board effective July 30, 2026. Mr. Tansey will not seek re-election at the company's 2027 Annual Meeting of Stockholders. His decision to retire was not a result of any disagreement with the company's operations, policies, or practices.

Inspire Medical Systems, Inc. announced the retirement of Casey M. Tansey from its Board of Directors, effective July 30. Mr. Tansey served on the Board for over eighteen years, having led the company's Series A financing in 2007 as a venture investor. The company expressed gratitude for his contributions and plans to announce a new Director in the near future.

Inspire Medical Systems, Inc. announced it will release its second quarter 2026 financial results after the close of trading on Monday, August 3. The company's management team will host a conference call on the same day at 5:00 p.m. Eastern Time to discuss the results and recent business developments. A webcast will be available for listeners, and registration is required for those planning to ask questions.

Inspire Medical Systems, Inc. announced its participation in various meetings with investors and analysts throughout June 2026. The company has furnished the presentation materials being used at these meetings as Exhibit 99.1 to its Form 8-K filing. These materials are also accessible on the Investor Relations page of the company's website.

Inspire Medical Systems, Inc. announced that its management team will participate in the Wells Fargo 2026 MedTech Innovation Spotlight. The presentation is scheduled for Friday, June 26, 2026, at 10:00 a.m. Eastern Time. A live webcast will be available, with a replay accessible for two weeks on the company's investor website.

Inspire Medical Systems, Inc. stockholders approved significant corporate governance changes at their 2026 Annual Meeting. Key approvals included an amendment and restatement of the 2018 Incentive Award Plan, authorizing an additional 2,600,000 shares for awards and implementing stricter vesting rules. Stockholders also approved an amendment to phase out the classified board structure, moving towards annual election of all directors starting in 2029. Additionally, directors were elected, the independent auditor was ratified, and executive compensation received advisory approval.